ATYR
Income statement / Annual
Last year (2024), aTyr Pharma, Inc.'s total revenue was $235.00 K,
a decrease of 33.43% from the previous year.
In 2024, aTyr Pharma, Inc.'s net income was -$64.02 M.
See aTyr Pharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$235.00 K |
$353.00 K |
$10.39 M |
$0.00 |
$10.46 M |
$422.00 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$1.70 M
|
$1.30 M
|
$17.29 M
|
$14.05 M
|
$746.00 K
|
$713.00 K
|
$900.00 K
|
$0.00
|
| Gross Profit |
$235.00 K
|
$353.00 K
|
$8.69 M
|
-$1.30 M
|
-$6.84 M
|
-$13.63 M
|
-$746.00 K
|
-$713.00 K
|
-$900.00 K
|
$0.00
|
| Gross Profit Ratio |
1
|
1
|
0.84
|
0
|
-0.65
|
-32.29
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$54.37 M
|
$42.29 M
|
$42.81 M
|
$23.26 M
|
$17.29 M
|
$14.05 M
|
$20.39 M
|
$30.07 M
|
$44.25 M
|
$34.50 M
|
| General & Administrative Expenses |
$13.78 M
|
$12.98 M
|
$13.98 M
|
$10.75 M
|
$9.08 M
|
$9.35 M
|
$0.00
|
$0.00
|
$0.00
|
$13.11 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
-$1.70 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$13.78 M
|
$12.98 M
|
$12.29 M
|
$10.75 M
|
$9.08 M
|
$9.35 M
|
$11.69 M
|
$16.37 M
|
$14.19 M
|
$13.11 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
-$1.30 M
|
-$17.29 M
|
-$14.05 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$68.15 M
|
$55.27 M
|
$55.10 M
|
$32.71 M
|
$9.08 M
|
$9.35 M
|
$32.07 M
|
$46.43 M
|
$58.44 M
|
$47.62 M
|
| Cost And Expenses |
$68.15 M
|
$55.27 M
|
$56.79 M
|
$34.02 M
|
$26.37 M
|
$23.40 M
|
$32.82 M
|
$47.15 M
|
$59.34 M
|
$47.62 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$65.00 K
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.54 M
|
$2.74 M
|
$1.70 M
|
$1.30 M
|
$1.27 M
|
$635.00 K
|
$746.00 K
|
$713.00 K
|
$900.00 K
|
$869.00 K
|
| EBITDA |
-$66.37 M |
-$52.18 M |
-$44.71 M |
-$32.47 M |
-$14.65 M |
-$22.34 M |
-$32.07 M |
-$46.43 M |
-$57.00 M |
-$45.35 M |
| EBITDA Ratio |
-282.44
|
-147.81
|
-4.3
|
0
|
-1.4
|
-52.95
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-289
|
-155.58
|
-4.47
|
0
|
-1.52
|
-54.45
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$3.89 M
|
$4.52 M
|
$1.06 M
|
$238.00 K
|
-$319.00 K
|
-$785.00 K
|
-$1.70 M
|
-$1.06 M
|
$1.44 M
|
-$357.00 K
|
| Income Before Tax |
-$64.02 M
|
-$50.40 M
|
-$45.34 M
|
-$33.78 M
|
-$16.23 M
|
-$23.76 M
|
-$34.52 M
|
-$48.21 M
|
-$57.90 M
|
-$47.97 M
|
| Income Before Tax Ratio |
-272.43
|
-142.77
|
-4.37
|
0
|
-1.55
|
-56.31
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$49.00 K
|
$0.00
|
| Net Income |
-$64.02 M
|
-$50.39 M
|
-$45.34 M
|
-$33.77 M
|
-$16.22 M
|
-$23.60 M
|
-$34.52 M
|
-$48.21 M
|
-$57.86 M
|
-$47.97 M
|
| Net Income Ratio |
-272.44
|
-142.75
|
-4.37
|
0
|
-1.55
|
-55.93
|
0
|
0
|
0
|
0
|
| EPS |
-0.86 |
-0.94 |
-1.6 |
-1.77 |
-1.77 |
-7.03 |
-16.13 |
-26.16 |
-34.2 |
-42.42 |
| EPS Diluted |
-0.86 |
-0.94 |
-1.6 |
-1.77 |
-1.77 |
-7.03 |
-16.13 |
-26.16 |
-34.2 |
-42.42 |
| Weighted Average Shares Out |
$74.26 M
|
$53.61 M
|
$28.42 M
|
$19.08 M
|
$9.16 M
|
$3.36 M
|
$2.14 M
|
$1.84 M
|
$1.69 M
|
$1.13 M
|
| Weighted Average Shares Out Diluted |
$74.26 M
|
$53.61 M
|
$28.42 M
|
$19.08 M
|
$9.16 M
|
$3.36 M
|
$2.14 M
|
$1.84 M
|
$1.69 M
|
$1.13 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
